­
­
­
­

Inventi Impact - Pharm Analysis & Quality Assurance

Articles

  • Inventi:ppaqa/28681/19
    PHARMACOLOGICAL EVALUATION OF BETA SECRETASE INHIBITORS
    Pandurangan Perumal*

    Alzheimer’s disease (AD) progresses due to beta amyloid aggregation and decreased acetylcholine level. Amyloid-Beta peptide (ABeta) formed by the continuous proteolytic processing of Beta-amyloid precursor protein (Beta APP) by Beta-secretase (BACE1) and Gamma-secretase (BACE2), plays a vital role in the pathogenesis of alzheimer’s disease (AD). Evaluated dipeptides and octapeptides exhibit inhibitory action against betasecretase enzyme. In-vitro enzyme inhibition assay was carried out for betasecretase enzyme and the IC50 value of DP I was found to be 0.0098 microgram/ml and the standard donepezil (AChE inhibitor) was found to be 0.065 microgram/ml. Based on the results the dipeptides and octapeptides were highly potent inhibition than control

    How to Cite this Article
    Pandurangan Perumal. Pharmacological Evaluation of Beta Secretase Inhibitors. Inventi Impact: Pharm Analysis & Quality Assurance, 2019(3):120-121, 2019.
    Download Full Text